A Clinical study of Aamalakiawaleham and Dadimadighritam in the management of Anaemia(Pandu).

A Randomized controlled clinical study of Aamalakiawaleham and Dadimadighritam in the management of Pandu.

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/01/022895

Enrollment

Registered

2020-01-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D50-D89- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

Interventions

Intervention1: Aamalakiawaleham: Aamalakiawaleham Is Prepared As Per Ayurved Text.Dose-5 gms,Frequency-twice a day,Duration-two months,Route- oral. Control Intervention1: Dadimadighritam: Dadimadigh

Eligibility

Inclusion criteria

Inclusion criteria: Patients having lakshanas of Pandu. Patients having Hb% between 7 to 11%.

Exclusion criteria

Exclusion criteria: Mrudbhakshanjanya & Garbhini pandu. Pandu associated with other chronic disprders like liver cirrhosis, ascitis, CCF,alcoholic liver diseases, HIV etc. Patients with Updrava of Pandu. Any type of malignant diseases e.g. Leukaemia metastatic cancer etc. Acute Heamorrhagical and infectious condition. Patient taking treatment from any other pathy for the same problem. Known patients of DM.

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of Aamalakiawaleham and Dadimadighritam in the management of Pandu.Timepoint: 2 Months with Follow Ups after 15 Days.	—

Secondary

Measure	Time frame
To Study The Side Effects of Drug If Any.Timepoint: 2 Months.	—

Countries

India

Contacts

Public ContactDrAaditya Mangesh Ketkar

PDEAs College of Ayurveda And Research Centre Akurdi Pune

khobragaderupali19@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026